PLUS1
122.88
4.68 (3.96%)
4.68 (3.96%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | MDGL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 4.68 | 3.96% | 122.88 | 20:00:00 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 122.88 | 117.6201 | 123.74 | 119.90 | 118.20 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 100.00 | 140.00 | 40.00 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,382 | 453,406 | $ 120.33 | $ 54,558,680 | 137,000 | 56.82 - 127.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:29:08 | 75 | $ 122.8817 | USD |
Madrigal Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.90B | 15.44M | 7.91M | $ - | $ - | -5.45 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -30.00k | 56.40% |
Madrigal Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/08/2020 | 06:02 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 9/03/2020 | 06:50 | GlobeNewswire Inc. | Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase.. |
| 8/26/2020 | 06:50 | GlobeNewswire Inc. | Madrigal Pharmaceuticals to Present Secondary Analyses of.. |
| 8/19/2020 | 19:41 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/19/2020 | 19:40 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/10/2020 | 19:08 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/06/2020 | 08:51 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDGL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 101.49 | 123.74 | 98.7075 | 109.56 | 270,580 | 21.39 | 21.08% |
| 1 Month | 106.90 | 123.74 | 98.7075 | 107.88 | 147,878 | 15.98 | 14.95% |
| 3 Months | 109.93 | 123.74 | 97.00 | 107.15 | 123,421 | 12.95 | 11.78% |
| 6 Months | 68.42 | 127.25 | 56.82 | 95.99 | 168,571 | 54.46 | 79.6% |
| 1 Year | 96.87 | 127.25 | 56.82 | 93.80 | 170,796 | 26.01 | 26.85% |
| 3 Years | 18.80 | 325.98 | 18.661 | 134.90 | 215,618 | 104.08 | 553.62% |
| 5 Years | 8.35 | 325.98 | 6.60 | 130.33 | 162,358 | 114.53 | 1,371.62% |
Madrigal Pharmaceuticals Description
| Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
